Skip to main content
. 2019 Nov 14;21:121. doi: 10.1186/s13058-019-1215-z

Fig. 3.

Fig. 3

Survival curves. Progression-free survival (a) and overall survival (b) for patients with ≥ 1 HER2amp CTC treated with T-DM1 (in yellow) and patients with ≥ 1 CTC but no HER2amp CTC, treated per standard of care (in black)